Capula Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $830K | Sell |
3,300
-21,700
| -87% | -$4.67M | ﹤0.01% | 311 |
|
|
2026
Q1 | $5.44M | Sell |
25,000
-700
| -3% | -$155K | 0.04% | 123 |
|
|
2025
Q4 | $5.87M | Sell |
25,700
-48,400
| -65% | -$11M | 0.03% | 146 |
|
|
2025
Q3 | $17.2M | Buy |
74,100
+70,200
| +1,800% | +$14.3M | 0.09% | 84 |
|
|
2025
Q2 | $724K | Sell |
3,900
-2,600
| -40% | -$483K | 0.01% | 192 |
|
|
2025
Q1 | $1.36M | Buy |
6,500
+4,300
| +195% | +$836K | 0.01% | 224 |
|
|
2024
Q4 | $391K | Sell |
2,200
-200
| -8% | -$36.8K | ﹤0.01% | 191 |
|
|
2024
Q3 | $474K | Sell |
2,400
-2,900
| -55% | -$541K | ﹤0.01% | 253 |
|
|
2024
Q2 | $909K | Buy |
5,300
+5,000
| +1,667% | +$828K | 0.01% | 161 |
|
|
2024
Q1 | $54.6K | Buy |
+300
| New | +$51.7K | ﹤0.01% | 451 |
|
|
2023
Q4 | – | Sell |
-6,200
| Closed | -$924K | – | 291 |
|
|
2023
Q3 | $924K | Sell |
6,200
-36,500
| -85% | -$5.36M | 0.02% | 232 |
|
|
2023
Q2 | $5.75M | Sell |
42,700
-146,100
| -77% | -$21.4M | 0.14% | 87 |
|
|
2023
Q1 | $30.1M | Buy |
188,800
+106,500
| +129% | +$16.3M | 0.36% | 57 |
|
|
2022
Q4 | $13.3M | Sell |
82,300
-63,000
| -43% | -$9.66M | 0.18% | 148 |
|
|
2022
Q3 | $19.5M | Buy |
145,300
+54,800
| +61% | +$7.86M | 0.26% | 108 |
|
|
2022
Q2 | $13.9M | Buy |
90,500
+38,500
| +74% | +$5.88M | 0.24% | 109 |
|
|
2022
Q1 | $8.43M | Buy |
+52,000
| New | +$7.55M | 0.12% | 150 |
|
|
2021
Q4 | – | Sell |
-130,400
| Closed | -$13.9M | – | 172 |
|
|
2021
Q3 | $13.9M | Buy |
130,400
+90,000
| +223% | +$10.3M | 0.17% | 104 |
|
|
2021
Q2 | $4.5M | Sell |
40,400
-53,500
| -57% | -$6.03M | 0.07% | 208 |
|
|
2021
Q1 | $10.2M | Buy |
93,900
+51,400
| +121% | +$5.5M | 0.2% | 131 |
|
|
2020
Q4 | $4.55M | Buy |
+42,500
| New | +$4.08M | 0.23% | 98 |
|
|
2020
Q3 | – | Sell |
-109,500
| Closed | -$10.8M | – | 135 |
|
|
2020
Q2 | $10.8M | Sell |
109,500
-47,600
| -30% | -$4.19M | 0.38% | 64 |
|
|
2020
Q1 | $12M | Sell |
157,100
-117,900
| -43% | -$10M | 0.43% | 62 |
|
|
2019
Q4 | $24.3M | Buy |
275,000
+200,000
| +267% | +$16.6M | 0.52% | 41 |
|
|
2019
Q3 | $5.68M | Buy |
75,000
+57,500
| +329% | +$3.94M | 0.12% | 162 |
|
|
2019
Q2 | $1.27M | Buy |
+17,500
| New | +$1.38M | 0.26% | 81 |
|
Other funds holding ABBV
Capula Management's ABBV Position: Q2 2026 in Review
Capula Management reduced its AbbVie (ABBV) stake by 50% in Q2 2026, selling an estimated $694K and leaving 3,168 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #314.
Capula Management first reported a position in ABBV in Q2 2019 and has held it in 19 quarters since. The position peaked at $7.03M in Q1 2020. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Capula Management held 3,168 shares of AbbVie worth $797K as of Q2 2026.
- Capula Management sold 3,224 AbbVie shares in Q2 2026, an estimated $694K.
- AbbVie made up ﹤0.01% of Capula Management's portfolio in Q2 2026, its #314 holding.
- Capula Management first reported a position in AbbVie in Q2 2019 and has held it in 19 quarters since.
- Capula Management's AbbVie position peaked at $7.03M in Q1 2020.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Capula Management's 13F filing for Q2 2026, filed 14 Aug 2026.